Hexameric MnII Dendrimer as MRI Contrast Agent

被引:55
|
作者
Zhu, Jiang [1 ,2 ]
Gale, Eric M. [1 ]
Atanasova, Iliyana [3 ]
Rietz, Tyson A. [1 ]
Caravan, Peter [1 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02141 USA
[2] North Sichuan Med Coll, Sichuan Key Lab Med Imaging, Nanchong, Peoples R China
[3] MIT, Cambridge, MA 02141 USA
关键词
dendrimers; imaging agents; manganese; magnetic resonance imaging; NMR spectroscopy; NEPHROGENIC SYSTEMIC FIBROSIS; METAL-COMPLEXES; WATER-EXCHANGE; MAGNETIC-FIELD; RESONANCE; RELAXATION; RELAXIVITY; GADOLINIUM; DISEASE; LIVER;
D O I
10.1002/chem.201403883
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A Mn-II chelating dendrimer was prepared as a contrast agent for MRI applications. The dendrimer comprises six tyrosine-derived [Mn(EDTA)(H2O)](2-) moieties coupled to a cyclotriphosphazene core. Variable temperature (ONMR)-O-17 spectroscopy revealed a single water co-ligand per Mn-II that undergoes fast water exchange (k(ex)=(3.0 +/- 0.1)x10(8)s(-1) at 37 degrees C). The 37 degrees C per Mn-II relaxivity ranged from 8.2 to 3.8mM(-1)s(-1) from 0.47 to 11.7T, and is sixfold higher on a per molecule basis. From this field dependence a rotational correlation time was estimated as 0.45(+/- 0.02)ns. The imaging and pharmacokinetic properties of the dendrimer were compared to clinically used [Gd(DTPA)(H2O)](2-) in mice at 4.7T. On first pass, the higher per ion relaxivity of the dendrimer resulted in twofold greater blood signal than for [Gd(DTPA)(H2O)](2-). Blood clearance was fast and elimination occurred through both the renal and hepatobiliary routes. This Mn-II containing dendrimer represents a potential alternative to Gd-based contrast agents, especially in patients with chronic kidney disease where the use of current Gd-based agents may be contraindicated.
引用
收藏
页码:14507 / 14513
页数:7
相关论文
共 50 条
  • [41] Accurate estimation of contrast agent dynamics in fast contrast enhanced MRI
    Huisman, HJ
    Barentsz, JO
    MEDICAL IMAGING 2000: PHYSIOLOGY AND FUNCTION FORM MULTIDIMENSIONAL IMAGES, 2000, 3978 : 338 - 346
  • [42] Factors influencing the design of dendrimer-based MRI contrast agents.
    Wiener, EC
    Brechbiel, W
    Lauterbur, PC
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U954 - U954
  • [43] Macromolecular MRI contrast agents with small dendrimer cores for functional kidney imaging
    Kobayashi, H
    Kawamoto, S
    Konishi, J
    Jo, S
    Brachbiel, MW
    Star, RA
    RADIOLOGY, 2002, 225 : 237 - 237
  • [44] Dendrimer-based MRI contrast agents: the effects of PEGylation on relaxivity and pharmacokinetics
    Kojima, Chie
    Turkbey, Baris
    Ogawa, Mikako
    Bernardo, Marcelino
    Regino, Celeste A. S.
    Bryant, L. Henry, Jr.
    Choyke, Peter L.
    Kono, Kenji
    Kobayashi, Hisataka
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2011, 7 (06) : 1001 - 1008
  • [45] SPIN-LABELED ARABINOGALACTAN AS MRI CONTRAST AGENT
    GALLEZ, B
    LACOUR, V
    DEMEURE, R
    DEBUYST, R
    DEJEHET, F
    DEKEYSER, JL
    DUMONT, P
    MAGNETIC RESONANCE IMAGING, 1994, 12 (01) : 61 - 69
  • [46] An evaluation of gadolinium polyoxornetalates as possible MRI contrast agent
    Feng, JH
    Li, XJ
    Pei, FK
    Sun, GY
    Zhang, X
    Liu, ML
    MAGNETIC RESONANCE IMAGING, 2002, 20 (05) : 407 - 412
  • [47] A polymeric micelle MRI contrast agent with changeable relaxivity
    Nakamura, Emiko
    Makino, Kimiko
    Okano, Teruo
    Yamamoto, Tatsuhiro
    Yokoyama, Masayuki
    JOURNAL OF CONTROLLED RELEASE, 2006, 114 (03) : 325 - 333
  • [48] Microgel-Based Thermosensitive MRI Contrast Agent
    Zheng, Xinwei
    Qian, Junchao
    Tang, Fei
    Wang, Zengrong
    Cao, Chunyan
    Zhong, Kai
    ACS Macro Letters, 2015, 4 (04): : 431 - 435
  • [49] GADOLINIUM-DTPA AS INTRAVENOUS MRI CONTRAST AGENT
    STEINER, RE
    BRITISH JOURNAL OF RADIOLOGY, 1985, 58 (690): : 582 - 582
  • [50] A Photocleavable Contrast Agent for Light-Responsive MRI
    Reessing, Friederike
    Huijsse, Sevrin E. M.
    Dierckx, Rudi A. J. O.
    Feringa, Ben L.
    Borra, Ronald J. H.
    Szymanski, Wiktor
    PHARMACEUTICALS, 2020, 13 (10) : 1 - 13